Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy - The Lancet Gastroenterology & Hepatology

B cells in pancreatic cancer stroma

Sulfonamides as tyrosine kinase modulators – A promising class of anticancer agents - ScienceDirect

Cancers, Free Full-Text

Scientific rationale for integrative and personalised strategies for pancreatic ductal adenocarcinoma management

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. - Abstract - Europe PMC

Frontiers Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options

Genes, Free Full-Text

The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy - The Lancet Gastroenterology & Hepatology

Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update - Cytotherapy

Myeloid-derived suppressor cells in cancer - ScienceDirect

Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment, Journal of Experimental & Clinical Cancer Research

The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers - Ren - 2023 - MedComm - Wiley Online Library

Envisioning the immune system to determine its role in pancreatic ductal adenocarcinoma: Culprit or victim? - ScienceDirect

PDF) Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma